|
|
Vaccine Detail
|
Prostate Cancer Vaccine ONY-P1 |
| Vaccine Information |
- Vaccine Name: Prostate Cancer Vaccine ONY-P1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007146
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CD40
gene engineering:
- Type: Recombinant protein preparation
- Description: (Huang et al., 2012)
- Detailed Gene Information: Click Here.
- Description: This is for Prostate Cancer (NCT00514072).A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant (Huang et al., 2012; NCIT_C71723).
|
| Host Response |
|
|
| References |
Huang et al., 2012: Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 2012; 120(15); 3030-3038. [PubMed: 22932804].
NCIT_C71723: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71723]
NCT00514072: [https://clinicaltrials.gov/ct2/show/NCT00514072]
|
|
